Research.Patient.info
B-cell Non-Hodgkins Lymphoma (B-NHL) research hub
2 indexed studies · 1 currently recruiting
- authorisedHuman Pharmacology (Phase I)- First administration to humans
REGN9220 in Combination with Odronextamab in Adult Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
This early-stage study tests a new combination of two medicines, REGN9220 and odronextamab. It is for adults with aggressive B-cell non-Hodgkin lymphoma that has returned or stopped responding to past treatments. Doctors want to check how safe these medicines are and find the best dose.
Belgium - recruitingPHASE1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
This study is testing two new drugs, Odronextamab and REGN5837, for people with aggressive B-cell Non-Hodgkin Lymphoma that has come back or not responded to previous treatments. It aims to find a safe dose and see how well they work together.
United States · France · Netherlands